Ignite Creation Date:
2024-05-06 @ 6:16 PM
Last Modification Date:
2024-10-26 @ 2:45 PM
Study NCT ID:
NCT05607108
Status:
RECRUITING
Last Update Posted:
2024-01-02
First Post:
2022-11-01
Brief Title:
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Phase 2 Trial of ZEN003694 in Squamous Cell Lung Cancer Patients Harboring NSD3 Amplification
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene
ZEN003694 is a type of drug called a BET inhibitor Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal BET proteins which may counteract the effect of NSD3 on tumor growth Blocking these proteins may slow or stop the growth of the cancer
ZEN003694 is a type of drug called a BET inhibitor Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal BET proteins which may counteract the effect of NSD3 on tumor growth Blocking these proteins may slow or stop the growth of the cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None